查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1961067

全球心血管器材市场：依器材类型、应用、最终用户和地区划分 - 市场规模、产业动态、机会分析和预测（2026-2035 年）

Global Cardiovascular Devices Market: By Device Type, Application, End User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 260 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球心血管器械市场呈现强劲成长势头，预计到 2025 年市场规模将达到 745.8 亿美元。这一惊人的市场规模预计将在未来十年内增长近一倍，到 2035 年达到 1573.2 亿美元。 2026 年至 2035 年预测期内的复合年增长率 (CAGR) 为 7.70%，反映了技术、监管和营运等多个领域多方面因素推动的强劲且持续的扩张。

推动市场快速成长的关键因素之一是脉衝场消融 (PFA) 和先进结构性心臟病治疗等创新技术的引入。 这些创新治疗方案正在改变心血管疾病的治疗方式，为传统手术提供创伤更小、更有效、更安全的替代方案。 这些技术的成功及其在临床实践中日益广泛的应用，推动了全球对心血管器械需求的成长。

主要市场趋势

心血管器械市场高度集中，少数几家主要企业占主导地位。美敦力、雅培、波士顿科学和爱德华生命科学等领导企业 拥有显着的市场占有率和影响力，引领着产业的创新和成长。这些公司正大力投资下一代科技的研发，尤其是在结构性心臟病解决方案、电生理学进展和人工智慧诊断工具方面。

身为市场领导者，美敦力拥有强劲的财务业绩和成长。在2026财年第二季度，美敦力公布的心血管相关收入为34.4亿美元，实现了9.3%的强劲内生成长。这一显着增长得益于Sphere-9脉衝场消融（PFA）系统和Evolut FX经导管主动脉瓣膜系统的成功推广。

爱德华生命科学公司（Edwards Lifesciences）被公认为结构性心臟器材领域的领导企业，其业绩表现强劲，2025年第二季销售额达15.3亿美元，年增11.9%。这一成长凸显了市场对瓣膜治疗（爱德华的核心业务）的持续需求。该公司持续的成功表明，结构性心臟介入治疗在心血管器械市场中的重要性，并预示着专注于该领域的公司仍拥有持续的发展机会。

核心成长驱动因子

心血管疾病盛行率的不断上升确保了心血管器械需求的长期持续增长。 仅在美国，预计到2030年将有约1210万人被诊断患有房颤，这反映出受这种常见心律不整影响的人群显着增加。 此外，截至2024年，美国约有1.279亿成年人患有某种形式的心血管疾病，凸显了这些疾病对公众健康的广泛影响。

新兴机会与趋势

基于人工智慧 (AI) 的诊断技术创新正在显着扩大心血管器械市场，提高了疾病检测和管理的准确性和效率。 AccuRhythm AI 等技术正在革新临床医生分析复杂心血管数据的方式，从而能够更快、更准确地诊断心律不整和其他心臟疾病。这些人工智慧驱动的工具利用机器学习演算法和先进的资料处理技术，帮助医疗专业人员做出明智的决策，改善患者预后，并简化临床工作流程。

优化障碍

美国食品药物管理局 (FDA) 和国际监管机构严格且耗时的审批流程对心血管器械市场构成了重大挑战。 这些程序对于确保新临床试验和产品上市的安全性和有效性至关重要，但往往会导致创新产品上市时间延长。虽然这些法规对于保护病患健康至关重要，但其冗长的审批流程可能会减缓产业创新的步伐。这种监管环境对缺乏大型企业那样雄厚资源和资金储备的中小型企业的影响尤为显着。

目录

第一章 摘要整理：全球心血管器材市场

第二章 报告概述

  • 研究框架
    • 研究目标
    • 市场定义
    • 市场区隔
  • 研究方法
    • 市场规模估算
    • 质性研究
    • 量化研究
    • 依地区划分的主要调查受访者组成
    • 资料三角验证
    • 研究假设

第三章 全球心血管器材市场概论

  • 产业价值链分析
    • 原料供应商（医用金属、聚合物等）电子元件）
    • 元件製造商（感知器、导管、导线、阀门）
    • 医疗器材製造商（支架、心律调节器、除颤器、心臟瓣膜）
    • 经销商和医疗保健提供者（医院、心臟中心、诊所）
    • 最终使用者（心血管疾病患者、门诊）
  • 行业展望
    • 心血管疾病盛行率上升及老化
    • 微创手术的普及
    • 科技趋势（人工智慧驱动）（监测、穿戴式装置、生物相容性材料）
    • 新兴市场医疗基础设施的扩张
  • PESTLE 分析
  • 波特五力分析
    • 议价能力供应商
    • 买方议价能力
    • 替代品威胁
    • 新进入者威胁
    • 竞争强度
  • 市场成长与展望
    • 市场收入估计与预测（2020-2035）
  • 市场吸引力分析
    • 依产品类型划分
  • 可操作的洞见（分析师建议）

第四章 竞争格局概览

  • 市场集中度
  • 公司占有率分析（基于价值，2025 年）
  • 竞争格局分析与基准分析

第五章：全球心血管器材市场分析

  • 市场动态与趋势
    • 成长驱动因素
    • 限制因素
    • 机遇
    • 主要趋势
  • 市场规模及预测（2020–2035）
    • 依装置类型划分
    • 依应用程式划分
    • 依最终用户划分
    • 依地区划分

第六章：北美心血管器材市场分析

第七章：欧洲心血管器材市场分析

第八章：亚太地区心血管器材市场分析

第九章：中东和非洲心血管器材市场分析

第十章：南美洲心血管器材市场分析

第11章 企业简介

  • Abbott
  • BIOTRONIK SE &Co. KG
  • Boston Scientific Corporation
  • Canon Medical Systems
  • B. Braun SE
  • Cardinal Health
  • Medtronic
  • LivaNova PLC
  • Siemens Healthcare GmbH
  • Edwards Lifesciences Corporation
  • GE Healthcare
  • W. L. Gore &Associates, Inc.
  • Other Prominent Players

第12章 附录

简介目录
Product Code: AA01261654

The global cardiovascular devices market is witnessing robust growth, with its valuation reaching USD 74.58 billion in 2025. This impressive market size is expected to nearly double over the next decade, with projections estimating it will reach USD 157.32 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 7.70% during the forecast period from 2026 to 2035, reflecting strong and sustained expansion driven by multiple factors across technological, regulatory, and operational domains.

One of the primary forces fueling this rapid market growth is the introduction of revolutionary technologies such as pulsed field ablation (PFA) and advanced structural heart therapies. These innovative treatment options are transforming how cardiovascular diseases are managed, offering less invasive, more effective, and safer alternatives to traditional procedures. The success and increasing clinical adoption of these technologies are contributing to heightened demand for cardiovascular devices globally.

Noteworthy Market Developments

The cardiovascular devices market is highly consolidated, with a handful of key players dominating the landscape. Leading companies such as Medtronic, Abbott, Boston Scientific, and Edwards Lifesciences hold significant market share and influence, shaping the direction of innovation and growth within the industry. These firms are heavily investing in the development of next-generation technologies, focusing particularly on structural heart solutions, electrophysiology advancements, and AI-powered diagnostic tools.

Medtronic stands out as the market leader, demonstrating strong financial performance and growth. In the second quarter of fiscal year 2026, Medtronic reported cardiovascular revenue of $3.44 billion, reflecting a robust 9.3% organic growth. This impressive expansion is largely attributed to the successful scaling of its Sphere-9 Pulsed Field Ablation (PFA) system and the Evolut FX transcatheter aortic valve system.

Edwards Lifesciences, recognized as a pure-play leader in structural heart devices, also showcased strong performance with $1.53 billion in sales for the second quarter of 2025, marking an 11.9% increase. This growth underscores the sustained demand for valve therapies, a core segment for Edwards. Their continued success highlights the critical importance of structural heart interventions in the cardiovascular devices market and signals ongoing opportunities for companies specializing in this area.

Core Growth Drivers

The rising prevalence of cardiovascular diseases guarantees a sustained and growing demand for cardiovascular devices in the long term. In the United States alone, it is projected that approximately 12.1 million people will be diagnosed with Atrial Fibrillation by 2030, reflecting a significant increase in the population affected by this common heart rhythm disorder. Furthermore, as of 2024, nearly 127.9 million US adults were living with some form of cardiovascular disease, underscoring the widespread impact these conditions have on public health.

Emerging Opportunity Trends

Innovation in artificial intelligence (AI)-based diagnostics is significantly expanding the cardiovascular devices market by enhancing the accuracy and efficiency of disease detection and management. Technologies such as AccuRhythm AI are revolutionizing the way clinicians analyze complex cardiovascular data, enabling faster and more precise diagnosis of arrhythmias and other heart conditions. By leveraging machine learning algorithms and advanced data processing, these AI-driven tools support healthcare professionals in making informed decisions, improving patient outcomes, and streamlining clinical workflows.

Barriers to Optimization

The rigorous and time-consuming approval processes imposed by the FDA and international regulatory bodies present significant challenges to the cardiovascular devices market. These procedures, which are essential to ensure the safety and efficacy of new clinical trials and product launches, often result in extended delays before innovative products can reach the market. While these regulations are critical for protecting patient health, the lengthy timelines involved can slow down the pace of innovation within the industry. This regulatory environment tends to disproportionately impact smaller firms, which may lack the extensive resources and capital reserves that larger companies possess.

Detailed Market Segmentation

By Device Type, the therapeutics and surgical devices category secured a commanding position within the cardiovascular devices market, capturing an impressive 77.5% share of total revenue. This strong dominance can be attributed to a significant transformation in medical practice, where there is a clear and growing preference for minimally invasive interventions over traditional open surgery. This shift reflects advancements in technology, improved patient outcomes, and a focus on reducing recovery times and associated risks.

By Application, the coronary artery disease sector held a dominant position within the global cardiovascular devices market, reflecting the ongoing critical importance of this medical condition. Coronary artery disease, a form of ischemic heart disease, continues to be the leading cause of death and disability worldwide. This persistent prevalence drives sustained demand for specialized cardiovascular devices designed to diagnose, treat, and manage the condition effectively.

By End User, hospitals stand out as the main purchasers of cardiovascular devices in today's market, serving as the central hub for acquiring and utilizing these critical medical products. Their role is particularly crucial because they manage the vast majority of emergency cardiovascular cases, including severe conditions like ST-Elevation Myocardial Infarctions (STEMI). Such emergencies demand swift and effective medical intervention, which in turn drives a substantial and urgent need for cardiovascular devices.

Segment Breakdown

By Device Type

  • Diagnostic & Monitoring
  • ECG
  • Holter Monitors
  • Event Monitors
  • Implantable Loop Recorders
  • Echocardiogram
  • Pet Scan
  • MRI
  • Cardiac CT
  • Doppler Fetal Monitors
  • Therapeutic & Surgical Devices
  • Pacemakers
  • Stents
  • Catheters and accessories
  • Guidewires
  • Cannulae
  • Electrosurgical Procedures
  • Valves
  • Occlusion Devices
  • Others

By Application

  • Cardiac Arrhythmia
  • Coronary Artery Disease
  • Heart Failure
  • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Geography Breakdown

  • North America maintains a strong and commanding presence in the global cardiovascular devices market, holding a substantial 45.68% share as of 2025. This prominent position is anchored by two main factors: significant localized demand and a highly developed healthcare infrastructure. In the United States alone, an estimated 127.9 million adults were managing cardiovascular conditions in 2024, creating an enormous and ongoing demand for cardiovascular devices. This large patient population ensures a steady and expanding market, as continuous treatment and intervention are necessary for effective disease management.
  • Additionally, the North American market, particularly the US, has seen a rapid and aggressive shift toward advanced, high-value cardiovascular therapies such as Pulsed Field Ablation (PFA). This innovative treatment approach has become a key driver of revenue growth in the region. For instance, Boston Scientific, a leading medical device company, generated over USD 1 billion in early revenue primarily due to the swift adoption of PFA technology within the US market. This rapid uptake highlights both the readiness of healthcare providers to embrace cutting-edge solutions and the region's capacity to support the commercialization of novel therapies, further solidifying North America's leadership in the cardiovascular devices sector.

Leading Market Participants

  • Abbott
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Canon Medical Systems
  • B. Braun SE
  • Cardinal Health
  • Medtronic
  • LivaNova PLC
  • Siemens Healthcare GmbH
  • Edwards Lifesciences Corporation
  • GE Healthcare
  • W. L. Gore & Associates, Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Cardiovascular Devices Market

Chapter 2. Report Description

  • 2.1. Research Framework
    • 2.1.1. Research Objective
    • 2.1.2. Market Definitions
    • 2.1.3. Market Segmentation
  • 2.2. Research Methodology
    • 2.2.1. Market Size Estimation
    • 2.2.2. Qualitative Research
      • 2.2.2.1. Primary & Secondary Sources
    • 2.2.3. Quantitative Research
      • 2.2.3.1. Primary & Secondary Sources
    • 2.2.4. Breakdown of Primary Research Respondents, By Region
    • 2.2.5. Data Triangulation
    • 2.2.6. Assumption for Study

Chapter 3. Global Cardiovascular Devices Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Material Suppliers (Medical-Grade Metals, Polymers, Electronic Components)
    • 3.1.2. Component Manufacturers (Sensors, Catheters, Leads, Valves)
    • 3.1.3. Device Manufacturers (Stents, Pacemakers, Defibrillators, Heart Valves)
    • 3.1.4. Distributors & Healthcare Providers (Hospitals, Cardiac Centers, Clinics)
    • 3.1.5. End Users (Patients with Cardiovascular Diseases, Ambulatory Care Settings)
  • 3.2. Industry Outlook
    • 3.2.1. Rising Prevalence of Cardiovascular Diseases & Aging Population
    • 3.2.2. Increasing Adoption of Minimally Invasive Procedures
    • 3.2.3. Technology Trends (AI-Enabled Monitoring, Wearable Devices, Biocompatible Materials)
    • 3.2.4. Expansion of Healthcare Infrastructure in Emerging Markets
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Product Type
  • 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Cardiovascular Devices Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Device Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Diagnostic & Monitoring
          • 5.2.1.1.1.1. ECG
          • 5.2.1.1.1.2. Holter Monitors
          • 5.2.1.1.1.3. Event Monitors
          • 5.2.1.1.1.4. Implantable Loop Recorders
          • 5.2.1.1.1.5. Echocardiogram
          • 5.2.1.1.1.6. Pet Scan
          • 5.2.1.1.1.7. MRI
          • 5.2.1.1.1.8. Cardiac CT
          • 5.2.1.1.1.9. Doppler Fetal Monitors
        • 5.2.1.1.2. Therapeutic & Surgical Devices
            • 5.2.1.1.2.1.1. Pacemakers
            • 5.2.1.1.2.1.2. Stents
            • 5.2.1.1.2.1.3. Catheters and accessories
            • 5.2.1.1.2.1.4. Guidewires
            • 5.2.1.1.2.1.5. Cannulae
            • 5.2.1.1.2.1.6. Electrosurgical Procedures
            • 5.2.1.1.2.1.7. Valves
            • 5.2.1.1.2.1.8. Occlusion Devices
            • 5.2.1.1.2.1.9. Others
    • 5.2.2. By Application
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Cardiac Arrhythmia
        • 5.2.2.1.2. Coronary Artery Disease
        • 5.2.2.1.3. Heart Failure
        • 5.2.2.1.4. Others
    • 5.2.3. By End User
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Hospitals
        • 5.2.3.1.2. Specialty Clinics
        • 5.2.3.1.3. Others
    • 5.2.4. By Region
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. North America
          • 5.2.4.1.1.1. The U.S.
          • 5.2.4.1.1.2. Canada
          • 5.2.4.1.1.3. Mexico
        • 5.2.4.1.2. Europe
          • 5.2.4.1.2.1. Western Europe
            • 5.2.4.1.2.1.1. The UK
            • 5.2.4.1.2.1.2. Germany
            • 5.2.4.1.2.1.3. France
            • 5.2.4.1.2.1.4. Italy
            • 5.2.4.1.2.1.5. Spain
            • 5.2.4.1.2.1.6. Rest of Western Europe
          • 5.2.4.1.2.2. Eastern Europe
            • 5.2.4.1.2.2.1. Poland
            • 5.2.4.1.2.2.2. Russia
            • 5.2.4.1.2.2.3. Rest of Eastern Europe
        • 5.2.4.1.3. Asia Pacific
          • 5.2.4.1.3.1. China
          • 5.2.4.1.3.2. India
          • 5.2.4.1.3.3. Japan
          • 5.2.4.1.3.4. South Korea
          • 5.2.4.1.3.5. Australia & New Zealand
          • 5.2.4.1.3.6. ASEAN
          • 5.2.4.1.3.7. Rest of Asia Pacific
        • 5.2.4.1.4. Middle East & Africa
          • 5.2.4.1.4.1. UAE
          • 5.2.4.1.4.2. Saudi Arabia
          • 5.2.4.1.4.3. South Africa
          • 5.2.4.1.4.4. Rest of MEA
        • 5.2.4.1.5. South America
          • 5.2.4.1.5.1. Argentina
          • 5.2.4.1.5.2. Brazil
          • 5.2.4.1.5.3. Rest of South America

Chapter 6. North America Cardiovascular Devices Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Device Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country

Chapter 7. Europe Cardiovascular Devices Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Device Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country

Chapter 8. Asia Pacific Cardiovascular Devices Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Device Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country

Chapter 9. Middle East & Africa Cardiovascular Devices Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Device Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country

Chapter 10. South America Cardiovascular Devices Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Device Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country

Chapter 11. Company Profile (Company Overview, Company Timeline, Organization Structure, Key Product landscape, Financial Matrix, Key Customers/Sectors, Key Competitors, SWOT Analysis, Contact Address, and Business Strategy Outlook)

  • 11.1. Abbott
  • 11.2. BIOTRONIK SE & Co. KG
  • 11.3. Boston Scientific Corporation
  • 11.4. Canon Medical Systems
  • 11.5. B. Braun SE
  • 11.6. Cardinal Health
  • 11.7. Medtronic
  • 11.8. LivaNova PLC
  • 11.9. Siemens Healthcare GmbH
  • 11.10. Edwards Lifesciences Corporation
  • 11.11. GE Healthcare
  • 11.12. W. L. Gore & Associates, Inc.
  • 11.13. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators